NO-donating NSAIDs and cancer: An overview with a note on whether NO is required for their action

Nitric Oxide - Biology and Chemistry

Volumn 19, Issue 2, 2008, Pages 199-204

  Rigas, Basil ^a   Williams, Jennie L ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

Cancer; Chemoprevention; Nitric oxide; NO aspirin; NO NSAIDs

Indexed keywords

ACETYLSALICYLIC ACID; INDOMETACIN; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE DONATING ASPIRIN; NITRIC OXIDE DONATING INDOMETACIN; NITRIC OXIDE DONATING NONSTEROIDAL ANTIINFLAMMATORY AGENT; NITRIC OXIDE DONOR; NONSTEROID ANTIINFLAMMATORY AGENT; REACTIVE OXYGEN METABOLITE;

APOPTOSIS; CANCER CELL; CANCER INCIDENCE; CARCINOGENESIS; CELL CULTURE; CELL RENEWAL; CHEMOPROPHYLAXIS; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR PROMOTION; XENOGRAFT;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; NEOPLASMS; NITRIC OXIDE; NITRIC OXIDE DONORS;

ANIMALIA;

EID: 47049091866     PISSN: 10898603     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.niox.2008.04.022     Document Type: Review

References (59)

1. Rigas B. The use of nitric oxide-donating nonsteroidal anti-inflammatory drugs in the chemoprevention of colorectal neoplasia. Curr. Opin. Gastroenterol. 23 (2007) 55-59
2. Gresele P., and Momi S. Pharmacologic profile and therapeutic potential of NCX 4016, a nitric oxide-releasing aspirin, for cardiovascular disorders. Cardiovasc. Drug Rev. 24 (2006) 148-168
3. Zhang Z.G., Zhang Y.H., Ji H., Qiu S.G., and Feng X.C. Design, synthesis and antiasthmatic activities of NO-donating seratrodast derivatives. Yao Xue Xue Bao 39 (2004) 705-710
4. Kakizawa H., Matsui F., Tokita Y., Hirano K., Ida M., Nakanishi K., Watanabe M., Sato Y., Okumura A., Kojima S., and Oohira A. Neuroprotective effect of nipradilol, an NO donor, on hypoxic-ischemic brain injury of neonatal rats. Early Hum. Dev. 83 (2007) 535-540
5. Kimura I. Medical benefits of using natural compounds and their derivatives having multiple pharmacological actions. Yakugaku Zasshi 126 (2006) 133-143
6. Thatcher G.R., Bennett B.M., and Reynolds J.N. NO chimeras as therapeutic agents in Alzheimer's disease. Curr. Alzheimer Res. 3 (2006) 237-245
7. del Soldato P., Sorrentino R., and Pinto A. NO-aspirins: a class of new anti-inflammatory and antithrombotic agents. Trends Pharmacol. Sci. 20 (1999) 319-323
8. Ellis J.L., Augustyniak M.E., Cochran E.D., Earl R.A., Garvey D.S., Gordon L.J., Janero D.R., Khanapure S.P., Letts L.G., Melim T.L., Murty M.G., Schwalb D.J., Shumway M.J., Selig W.M., Trocha A.M., Young D.V., and Zemtseva I.S. NMI-1182, a gastro-protective cyclo-oxygenase-inhibiting nitric oxide donor. Inflammopharmacology 12 (2005) 521-534
9. Fiorucci S., Santucci L., Gresele P., Faccino R.M., Del Soldato P., and Morelli A. Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology 124 (2003) 600-607
10. Thatcher G.R. An introduction to NO-related therapeutic agents. Curr. Top. Med. Chem. 5 (2005) 597-601
11. Thatcher G.R., Bennett B.M., and Reynolds J.N. Nitric oxide mimetic molecules as therapeutic agents in Alzheimer's disease. Curr. Alzheimer Res. 2 (2005) 171-182
12. Thatcher G.R., Nicolescu A.C., Bennett B.M., and Toader V. Nitrates and NO release: contemporary aspects in biological and medicinal chemistry. Free Radic. Biol. Med. 37 (2004) 1122-1143
13. Hagos G.K., Carroll R.E., Kouznetsova T., Li Q., Toader V., Fernandez P.A., Swanson S.M., and Thatcher G.R. Colon cancer chemoprevention by a novel NO chimera that shows anti-inflammatory and antiproliferative activity in vitro and in vivo. Mol. Cancer Ther. 6 (2007) 2230-2239
14. 2-acetoxymethyl-protected diazeniumdiolate-based NSAIDs (NONO-NSAIDs): synthesis, nitric oxide release, and biological evaluation studies. Bioorg. Med. Chem. 15 (2007) 4767-4774
15. Kiziltepe T., Hideshima T., Ishitsuka K., Ocio E.M., Raje N., Catley L., Li C.Q., Trudel L.J., Yasui H., Vallet S., Kutok J.L., Chauhan D., Mitsiades C.S., Saavedra J.E., Wogan G.N., Keefer L.K., Shami P.J., and Anderson K.C. JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells. Blood 110 (2007) 709-718
16. Chakrapani H., Wilde T.C., Citro M.L., Goodblatt M.M., Keefer L.K., and Saavedra J.E. Synthesis, nitric oxide release, and anti-leukemic activity of glutathione-activated nitric oxide prodrugs: Structural analogues of PABA/NO, an anti-cancer lead compound. Bioorg. Med. Chem. 16 (2008) 2657-2664
17. Carini M., Aldini G., Orioli M., Piccoli A., Rossoni G., and Maffei Facino R. Nitric oxide release and distribution following oral and intraperitoneal administration of nitroaspirin (NCX 4016) in the rat. Life Sci. 74 (2004) 3291-3305
18. Carini M., Aldini G., Orioli M., Piccoli A., Tocchetti P., and Facino R.M. Chemiluminescence and LC-MS/MS analyses for the study of nitric oxide release and distribution following oral administration of nitroaspirin (NCX 4016) in healthy volunteers. J. Pharm. Biomed. Anal. 35 (2004) 277-287
19. Williams J.L., Borgo S., Hasan I., Castillo E., Traganos F., and Rigas B. Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NSAIDs) alter the kinetics of human colon cancer cell lines more effectively than traditional NSAIDs: implications for colon cancer chemoprevention. Cancer Res. 61 (2001) 3285-3289
20. Yeh R.K., Chen J., Williams J.L., Baluch M., Hundley T.R., Rosenbaum R.E., Kalala S., Traganos F., Benardini F., del Soldato P., Kashfi K., and Rigas B. NO-donating nonsteroidal antiinflammatory drugs (NSAIDs) inhibit colon cancer cell growth more potently than traditional NSAIDs: a general pharmacological property?. Biochem. Pharmacol. 67 (2004) 2197-2205
21. Huguenin S., Vacherot F., Fleury-Feith J., Riffaud J.P., Chopin D.K., Bolla M., and Jaurand M.C. Evaluation of the antitumoral potential of different nitric oxide-donating non-steroidal anti-inflammatory drugs (NO-NSAIDs) on human urological tumor cell lines. Cancer Lett. 218 (2005) 163-170
22. Huguenin S., Vacherot F., Kheuang L., Fleury-Feith J., Jaurand M.C., Bolla M., Riffaud J.P., and Chopin D.K. Antiproliferative effect of nitrosulindac (NCX 1102), a new nitric oxide-donating non-steroidal anti-inflammatory drug, on human bladder carcinoma cell lines. Mol. Cancer Ther. 3 (2004) 291-298
23. Kashfi K., Ryann Y., Qiao L.L., Williams J.L., Chen J., Del Soldato P., Traganos F., and Rigas B. Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells: evidence of a tissue type-independent effect. J. Pharmacol. Exp. Ther. 303 (2002) 1273-1282
24. Williams J.L., Kashfi K., Ouyang N., del Soldato P., Kopelovich L., and Rigas B. NO-donating aspirin inhibits intestinal carcinogenesis in Min (APC(Min/+)) mice. Biochem. Biophys. Res. Commun. 313 (2004) 784-788
25. Rao C.V., Reddy B.S., Steele V.E., Wang C.X., Liu X., Ouyang N., Patlolla J.M., Simi B., Kopelovich L., and Rigas B. Nitric oxide-releasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: effects on molecular targets. Mol. Cancer Ther. 5 (2006) 1530-1538
26. Tesei A., Ulivi P., Fabbri F., Rosetti M., Leonetti C., Scarsella M., Zupi G., Amadori D., Bolla M., and Zoli W. In vitro and in vivo evaluation of NCX 4040 cytotoxic activity in human colon cancer cell lines. J. Transl. Med. 3 (2005) 7
27. Leonetti C., Scarsella M., Zupi G., Zoli W., Amadori D., Medri L., Fabbri F., Rosetti M., Ulivi P., Cecconetto L., Bolla M., and Tesei A. Efficacy of a nitric oxide-releasing nonsteroidal anti-inflammatory drug and cytotoxic drugs in human colon cancer cell lines in vitro and xenografts. Mol. Cancer Ther. 5 (2006) 919-926
28. Ouyang N., Williams J.L., and Rigas B. NO-donating aspirin isomers downregulate peroxisome proliferator-activated receptor (PPAR)δ expression in APCmin/+ mice proportionally to their tumor inhibitory effect: Implications for the role of PPARδ in carcinogenesis. Carcinogenesis 27 (2006) 232-239
29. Kashfi K., Borgo S., Williams J.L., Chen J., Gao J., Glekas A., Benedini F., Del Soldato P., and Rigas B. Positional isomerism markedly affects the growth inhibition of colon cancer cells by nitric oxide-donating aspirin in vitro and in vivo. J. Pharmacol. Exp. Ther. 312 (2005) 978-988
30. Tesei A., Rosetti M., Ulivi P., Fabbri F., Medri L., Vannini I., Bolla M., Amadori D., and Zoli W. Study of molecular mechanisms of pro-apoptotic activity of NCX 4040, a novel nitric oxide-releasing aspirin, in colon cancer cell lines. J. Transl. Med. 5 (2007) 52
31. Rosetti M., Tesei A., Ulivi P., Fabbri F., Vannini I., Brigliadori G., Amadori D., Bolla M., and Zoli W. Molecular characterization of cytotoxic and resistance mechanisms induced by NCX 4040, a novel NO-NSAID, in pancreatic cancer cell lines. Apoptosis 11 (2006) 1321-1330
32. Gao J., Liu X., and Rigas B. Nitric oxide-donating aspirin induces apoptosis in human colon cancer cells through induction of oxidative stress. Proc. Natl. Acad. Sci. USA 102 (2005) 17207-17212
33. Hundley T.R., and Rigas B. Nitric oxide-donating aspirin inhibits colon cancer cell growth via mitogen-activated protein kinase activation. J. Pharmacol. Exp. Ther. 316 (2006) 25-34
34. Spiegel A., Hundley T.R., Chen J., Gao J., Ouyang N., Liu X., Go M.F., Tsioulias G.J., Kashfi K., and Rigas B. NO-donating aspirin inhibits both the expression and catalytic activity of inducible nitric oxide synthase in HT-29 human colon cancer cells. Biochem. Pharmacol. 70 (2005) 993-1000
35. Williams J.L., Ji P., Ouyang N., Liu X., and Rigas B. NO-donating aspirin inhibits the activation of NF-κB in human cancer cell lines and Min mice. Carcinogenesis 29 (2008) 390-397
36. Williams J.L., Nath N., Chen J., Hundley T.R., Gao J., Kopelovich L., Kashfi K., and Rigas B. Growth inhibition of human colon cancer cells by nitric oxide (NO)-donating aspirin is associated with cyclooxygenase-2 induction and beta-catenin/T-cell factor signaling, nuclear factor-κB, and NO synthase 2 inhibition: implications for chemoprevention. Cancer Res. 63 (2003) 7613-7618
37. Gao J., Kashfi K., Liu X., and Rigas B. NO-donating aspirin induces phase II enzymes in vitro and in vivo. Carcinogenesis 27 (2006) 803-810
38. McIlhatton M.A., Tyler J., Burkholder S., Ruschoff J., Rigas B., Kopelovich L., and Fishel R. Nitric oxide-donating aspirin derivatives suppress microsatellite instability in mismatch repair-deficient and hereditary nonpolyposis colorectal cancer cells. Cancer Res. 67 (2007) 10966-10975
39. Rigas B., and Kashfi K. Nitric-oxide-donating NSAIDs as agents for cancer prevention. Trends Mol. Med. 10 (2004) 324-330
40. S. NicOx, NicOx provides an update on NCX 4016 (Press release), 2007. Available from: ; accessed November 23, 2007.
41. Wink D.A., and Mitchell J.B. Nitric oxide and cancer: an introduction. Free Radic. Biol. Med. 34 (2003) 951-954
42. Anuar F., Whiteman M., Bhatia M., and Moore P.K. Flurbiprofen and its nitric oxide-releasing derivative protect against septic shock in rats. Inflamm. Res. 55 (2006) 498-503
43. Carini M., Aldini G., Stefani R., Orioli M., and Facino R.M. Nitrosylhemoglobin, an unequivocal index of nitric oxide release from nitroaspirin: in vitro and in vivo studies in the rat by ESR spectroscopy. J. Pharm. Biomed. Anal. 26 (2001) 509-518
44. Govoni M., Casagrande S., Maucci R., Chiroli V., and Tocchetti P. In vitro metabolism of (nitrooxy)butyl ester nitric oxide-releasing compounds: comparison with glyceryl trinitrate. J. Pharmacol. Exp. Ther. 317 (2006) 752-761
45. Perini R., Fiorucci S., and Wallace J.L. Mechanisms of nonsteroidal anti-inflammatory drug-induced gastrointestinal injury and repair: a window of opportunity for cyclooxygenase-inhibiting nitric oxide donors. Can. J. Gastroenterol. 18 (2004) 229-236
46. Brzozowski T., Konturek P.C., Konturek S.J., Sliwowski Z., Drozdowicz D., Kwiecien S., Pajdo R., Ptak A., Pawlik M., and Hahn E. Gastroprotective and ulcer healing effects of nitric oxide-releasing non-steroidal anti-inflammatory drugs. Dig. Liver Dis. 32 (2000) 583-594
47. Wallace J.L. Nitric oxide, aspirin-triggered lipoxins and NO-aspirin in gastric protection. Inflamm. Allergy Drug Targets 5 (2006) 133-137
48. Scatena R., Bottoni P., Martorana G.E., and Giardina B. Nitric oxide donor drugs: an update on pathophysiology and therapeutic potential. Expert Opin. Investig. Drugs 14 (2005) 835-846
49. Liu Q., Chan S.T., and Mahendran R. Nitric oxide induces cyclooxygenase expression and inhibits cell growth in colon cancer cell lines. Carcinogenesis 24 (2003) 637-642
50. Hamilton D., and Batist G. Glutathione analogues in cancer treatment. Curr. Oncol. Rep. 6 (2004) 116-122
51. Frederiksen L.J., Siemens D.R., Heaton J.P., Maxwell L.R., Adams M.A., and Graham C.H. Hypoxia induced resistance to doxorubicin in prostate cancer cells is inhibited by low concentrations of glyceryl trinitrate. J. Urol. 170 (2003) 1003-1007
52. Huerta-Yepez S., Vega M., Jazirehi A., Garban H., Hongo F., Cheng G., and Bonavida B. Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-κB and inhibition of Bcl-xl expression. Oncogene 23 (2004) 4993-5003
53. Dairou J., Atmane N., Rodrigues-Lima F., and Dupret J.M. Peroxynitrite irreversibly inactivates the human xenobiotic-metabolizing enzyme arylamine N-acetyltransferase 1 (NAT1) in human breast cancer cells: a cellular and mechanistic study. J. Biol. Chem. 279 (2004) 7708-7714
54. Park I.C., Woo S.H., Park M.J., Lee H.C., Lee S.J., Hong Y.J., Lee S.H., Hong S.I., and Rhee C.H. Ionizing radiation and nitric oxide donor sensitize Fas-induced apoptosis via up-regulation of Fas in human cervical cancer cells. Oncol. Rep. 10 (2003) 629-633
55. Wang D., Lu S., and Dong Z. Regulation of TGF-beta1 gene transcription in human prostate cancer cells by nitric oxide. Prostate 67 (2007) 1825-1833
56. Ambs S., Bennett W.P., Merriam W.G., Ogunfusika M.O., Oser S.M., Harrington A.M., Shields P.G., Felley-Bosco E., Hussain S.P., and Harris C.C. Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer. J. Natl. Cancer Inst. 91 (1999) 86-88
57. Kashfi K., and Rigas B. The mechanism of action of nitric oxide-donating aspirin. Biochem. Biophys. Res. Commun. 358 (2007) 1096-1101
58. Hulsman N., Medema J.P., Bos C., Jongejan A., Leurs R., Smit M.J., de Esch I.J., Richel D., and Wijtmans M. Chemical insights in the concept of hybrid drugs: the antitumor effect of nitric oxide-donating aspirin involves a quinone methide but not nitric oxide nor aspirin. J. Med. Chem. 50 (2007) 2424-2431
59. Rigas B., and Kozoni V. The novel phenylester anticancer compounds: Study of a derivative of aspirin (phoshoaspirin). Int. J. Oncol. 32 (2008) 97-100